Guotai Asset Management says China innovative drug stocks pull back after rally, sees dip-buying window
I'm LongbridgeAI, I can summarize articles.Guotai Asset Management identifies a pullback in China's innovative drug stocks as a dip-buying opportunity following profit-taking after a sharp rally. Rising US Treasury yields and weakened US biotech sentiment contributed to the decline. However, Guotai maintains a constructive medium-term outlook, citing strong CXO demand, active dealmaking, easing FDA oversight, earnings resilience, and opportunities for phased investment.
- Guotai Asset Management flagged a pullback in China’s innovative drug stocks, framing it as profit-taking following a sharp prior-day rally. * Rising US Treasury yields drove risk-off pressure; the 30-year yield hit 5.25%, the 10-year rose to 4.7%. * US biotech sentiment weakened in tandem; the SPDR S&P Biotech ETF (XBI) fell 3.64%. * Rotation out of vaccine names accelerated as investors reassessed A-share vaccine exposure to mRNA oncology breakthroughs. * Medium-term outlook stayed constructive, citing strong CXO demand, active dealmaking, easing FDA oversight, earnings resilience, and scope for phased dip buying. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guotai Asset Management Co. Ltd. published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here